Viking's VK2735 Obesity Data Spurs Stock Surge, Lilly and Novo Fall — SkimNews
Get the Finance newsletter
Daily finance — markets, central banks, M&A, the prints that move money. Free.
- Viking Therapeutics stock skyrocketed after the company announced positive topline results from a maintenance study of its obesity drug candidate VK2735, a GLP-1/GIP dual agonist.
- The VK2735 maintenance study demonstrated the promise of multiple maintenance dosing regimens, per Viking's PR release carried by PR Newswire.
- Eli Lilly and Novo Nordisk — the dominant players in the injectable obesity drug market — both saw their shares fall as Viking's data raised the prospect of a new competitive entrant.
- VKTX shares spiked sharply on the news, according to the Investor's Business Daily headline, reflecting investor enthusiasm for a potential third major player in the GLP-1 obesity space.
Why it matters: The obesity drug market is currently a duopoly between Eli Lilly (Zepbound/Mounjaro) and Novo Nordisk (Wegovy/Ozempic), with both companies' valuations resting heavily on continued GLP-1 dominance. Viking's VK2735 data — positive across multiple maintenance dosing regimens — introduces credible third-competitor risk, which is why the incumbent stocks sold off while VKTX soared: investors are repricing the competitive landscape in real time.
Ask SkimNews
